



## Palliative Chronic Lymphocytic Leukemia (CLL) Regimens

The following table lists the evidence-informed regimens (both IV and non-IV) for CLL used in the palliative setting. It is expected that the prescribing oncologist will select the regimen from the list of evidence-informed regimens that is most appropriate for their patient taking account of a variety of disease-specific and patient-related factors.

**Regimens highlighted in red contain an expensive drug that is not currently publicly funded for the regimen and treatment intent.**

Regimens highlighted in blue contain an expensive drug that is not currently publicly funded but where there is a universal compassionate access program in place. The administration of the drug supported by the systemic treatment funding model, but not the cost of drug.

| Chronic Lymphocytic Leukemia |   |
|------------------------------|---|
| Regimen Code                 | Regimen Abstract  |
| BEND                         | Bendamustine 100 mg/m <sup>2</sup> IV days 1-2.<br>Q28 days   |
| CHLO                         | <i>Dose and frequency may vary, one option is:</i><br>Chlorambucil 6 mg/m <sup>2</sup> PO days 1-14.<br>Q28 days<br><br>Can be given with or without Prednisone   |
| CHLO+OBIN                    | Chlorambucil 0.5 mg/kg PO days 1, 15 of each cycle<br>oBINutuzumab 1000 mg IV days 1, 8, 15 for cycle 1<br>THEN oBINutuzumab 1000 mg IV day 1 of cycles 2 to 6<br>(Cycle 1 first dose of oBINutuzumab split over 2 days: 100 mg IV day 1 and 900 mg IV day 2)<br>Q28 days |
| CVP                          | Cyclophosphamide 750 mg/m <sup>2</sup> IV day 1;<br>vinCRISStine 1.4 mg/m <sup>2</sup> (max 2 mg) IV day 1;<br>Prednisone 100 mg PO daily, days 1-5.<br>Q21 days  |
| CVP(PO)                      | Cyclophosphamide 400 mg/m <sup>2</sup> PO days 1-5;<br>vinCRISStine 1.4 mg/m <sup>2</sup> (max 2 mg) IV day 1;<br>Prednisone 100 mg PO daily, days 1-5.<br>Q21 days   |
| CYCL(PO)                     | <i>Dose and frequency may vary, two options are:</i><br>Cyclophosphamide 500 mg PO Weekly<br>Or<br>Cyclophosphamide 50 mg PO daily<br>Can be given with or without Prednisone   |

## Chronic Lymphocytic Leukemia

| Regimen Code | Regimen Abstract   |
|--------------|--|
| DEXA(HD)     | Dexamethasone 187.5 mg/m <sup>2</sup> PO daily for 4 days.<br>Q28 days   |
| FC           | Fludarabine 25 mg/m <sup>2</sup> IV days 1-3;<br>Cyclophosphamide 250 mg/m <sup>2</sup> IV days 1-3.<br>Q28 days   |
| FC(PO)       | Fludarabine 25 mg/m <sup>2</sup> PO days 1-5;<br>Cyclophosphamide 150 mg/m <sup>2</sup> PO days 1-5.<br>Q28 days   |
| FC(PO)+R     | Fludarabine 25 mg/m <sup>2</sup> PO days 1-5<br>Cyclophosphamide 150 mg/m <sup>2</sup> PO days 1-5;<br>riTUXimab 375 mg/m <sup>2</sup> IV (day 1 cycle 1)<br>THEN riTUXimab 500 mg/m <sup>2</sup> IV (day 1 cycles 2-6).<br>Q28 days   |
| FC+R         | Fludarabine 25 mg/m <sup>2</sup> IV days 1-3;<br>Cyclophosphamide 250 mg/m <sup>2</sup> IV days 1-3;<br>riTUXimab 375 mg/m <sup>2</sup> IV (day 1 cycle 1)<br>THEN riTUXimab 500 mg/m <sup>2</sup> IV (day 1 cycles 2-6).<br>Q28 days  |
| FCM          | Fludarabine 25 mg/m <sup>2</sup> IV days 1-3;<br>Cyclophosphamide 200-250 mg/m <sup>2</sup> IV days 1-3;<br>mitoXANTrone 6 mg/m <sup>2</sup> IV day 1 ONLY.<br>Q28 days  |
| FCM+R        | Fludarabine 25 mg/m <sup>2</sup> IV days 1-3;<br>Cyclophosphamide 200-250 mg/m <sup>2</sup> IV days 1-3;<br>mitoXANTrone 6 mg/m <sup>2</sup> IV day 1 ONLY;<br>riTUXimab 375 mg/m <sup>2</sup> IV (day 1 cycle 1)<br>THEN riTUXimab 500 mg/m <sup>2</sup> IV (day 1 cycles 2-6).<br>Q28 days |
| FLUD         | Fludarabine 25 mg/m <sup>2</sup> IV days 1-5.<br>Q28 days  |
| FLUD(PO)     | Fludarabine 40 mg/m <sup>2</sup> PO days 1-5.<br>Q28 days  |
| FLUD(PO)+R   | Fludarabine 40 mg/m <sup>2</sup> PO daily days 1- 5;<br>riTUXimab 375 mg/m <sup>2</sup> IV (day 1 cycle 1)<br>THEN riTUXimab 500 mg/m <sup>2</sup> IV (day 1 cycles 2-6).<br>Q28 days  |
| FLUD+R       | Fludarabine 25 mg/m <sup>2</sup> IV days 1-5;<br>riTUXimab 375 mg/m <sup>2</sup> IV (day 1 cycle 1)<br>THEN riTUXimab 500 mg/m <sup>2</sup> IV (day 1 cycles 2-6).<br>Q28 days   |
| IBRU         | iBRUtinib 420 mg PO daily  |
| IDEL+RITU    | Idelalisib 150 mg PO BID until disease progression<br>riTUXimab 375 mg/m <sup>2</sup> IV day 1, week 1   |

## Chronic Lymphocytic Leukemia

| Regimen Code | Regimen Abstract  |
|--------------|---|
|              | <p>THEN<br/>riTUXimab 500 mg/m<sup>2</sup> IV day 1, weeks 3, 5, 7, 9, 13, 17, 21 (total 8 infusions)</p> <p><i>Note: **Report as Regimen Code: IDEL after riTUXimab portion is complete**</i></p>  |
| MTPR(HD)     | Methylprednisolone 1000 mg/m <sup>2</sup> IV days 1-5<br>Q28 days   |
| PRED(HD)     | Prednisone 1250 mg/m <sup>2</sup> PO daily, days 1-5<br>Q28 days  |
| ALEM         | <p>Week 1:<br/>Alemtuzumab 3 mg IV/SC (first dose), 10 mg IV/SC (second dose), 30 mg IV/SC (third dose).</p> <p>Weeks 2 to 13:<br/>Alemtuzumab 30 mg IV/SC 3x weekly</p> <p>Use ALEM(IV) in T-Cell Prolymphocytic Leukemia<br/>Not publicly funded. Universal compassionate access program available</p>  |
| ALEM(IV)     | <p>Week 1:<br/>Alemtuzumab 3 mg IV (first dose), 10 mg IV (second dose), 30 mg IV (third dose)</p> <p>Weeks 2 to 13:<br/>Alemtuzumab 30 mg IV 3x weekly</p> <p>For use in T-Cell Prolymphocytic Leukemia<br/>Not publicly funded. Universal compassionate access program available</p>  |
| ALEM+RITU    | <p>Week 1:<br/>Alemtuzumab 3 mg IV/SC (first dose), 10 mg IV/SC (second dose), 30 mg IV/SC (third dose).</p> <p>Weeks 2 to 13:<br/>Alemtuzumab 30 mg IV/SC 3x weekly</p> <p>Not publicly funded. Universal compassionate access program available</p> <p><b>riTUXimab 375 mg/m<sup>2</sup> IV weekly for 4 weeks. – Not currently publicly funded for this regimen and intent</b></p>               |
| BEND+RITU    | <p><b>Bendamustine 90 mg/m<sup>2</sup> IV days 1-2; – Not currently publicly funded for this regimen and intent</b></p> <p><b>RiTUXimab 375 mg/m<sup>2</sup> IV day 1, cycle 1 – Not currently publicly funded for this regimen and intent</b></p> <p><b>RiTUXimab 500 mg/m<sup>2</sup> IV day 1, cycles 2 to 6 – Not currently publicly funded for this regimen and intent</b></p> <p>Q28 days</p> |
| FCM+ALEM     | <p>Fludarabine 25 mg/m<sup>2</sup> IV days 1-3;<br/>Cyclophosphamide 200 mg/m<sup>2</sup> IV days 1-3;<br/>MitoXANTRONE 8 mg/m<sup>2</sup> IV day 1</p> <p>Q28 days</p> <p>Alemtuzumab week 1:<br/>Alemtuzumab 3 mg IV/SC (first dose), 10 mg IV (second dose), 30 mg IV (third dose)</p> <p>Weeks 2 to 13:<br/>Alemtuzumab 30 mg IV/SC 3 x weekly</p>  |

## Chronic Lymphocytic Leukemia

| Regimen Code | Regimen Abstract   |
|--------------|--|
|              | Not publicly funded. Universal compassionate access program available.   |
| OFAT         | oFAtumumab 300 mg IV day 1<br>THEN<br>oFAtumumab 2000 mg IV starting week 2, Q7 days x 7<br>THEN<br>oFAtumumab 2000 mg IV starting week 12 Q28 days x 4<br>Not publicly funded. Universal compassionate access program available   |
| VENE         | Week 1:<br><b>Venetoclax 20 mg PO daily – not currently publicly funded for this regimen and intent;</b><br>Week 2:<br><b>Venetoclax 50 mg PO daily;</b><br>Week 3:<br><b>Venetoclax 100 mg PO daily;</b><br>Week 4:<br><b>Venetoclax 200 mg PO daily;</b><br>THEN<br><b>Venetoclax 400 mg PO daily.</b> |

Last Updated: November 2017